Inhibikase is developing and commercializing small-molecule kinase inhibitor therapeutics for the safe and effective treatment of neurological diseases inside and outside of the brain, on developing technologies to improve the efficiency of drug delivery and drug penetration of kinase inhibitor therapies inside and outside of the brain and focused on developing novel strategies for the treatment of neurological infections. The IKT stock yearly return is shown above.
The yearly return on the IKT stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the IKT annual return calculation with any dividends reinvested as applicable (on ex-dates).
|